Key Highlights
● Acadia's Phase 2 RADIANT study narrowly missed its primary endpoint on the SAPS-H+D scale at six weeks.
● The company says a secondary measure and a favorable safety profile support moving straight to Phase 3 trials.
● CEO Catherine Owen Adams said the data support continuation of the Phase 3 ADP program for remlifanserin.
● Acadia will present detailed RADIANT results at the CTAD conference in Boston this November.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a component of the Nasdaq Biotechnology Index, announced on September 24, 2026 what it called Phase 3 enabling topline results from the Phase 2 portion of its RADIANT trial testing remlifanserin for Alzheimer's disease psychosis, even though the drug narrowly missed its primary statistical endpoint.
The Primary Endpoint Miss
On the primary endpoint, the Scale for Assessment of Positive Symptoms-Hallucinations and Delusions subscales, or SAPS-H+D, measured at six weeks, the trial narrowly missed statistical significance, with the company citing a p-value of 0.0603, just above the conventional 0.05 threshold typically required to declare a result statistically significant.
The Safety Case, in the Company's Words
Acadia's press release describes a favorable safety profile across both doses tested, with rates of adverse events, serious adverse events, and discontinuations described as consistent with what the company has observed in prior studies of the drug. That safety consistency is part of the case Acadia is making for advancing the program despite the near-miss on the primary efficacy measure.
What Acadia Said
Acadia CEO Catherine Owen Adams said in the release that the company is pleased the Phase 2 RADIANT data support continuation of the Phase 3 ADP program, pointing to the totality of the evidence rather than the primary endpoint result in isolation as the basis for that decision.
Why a Narrow Miss Isn't a Stop Sign Here
Acadia's decision to press ahead rests on a combination of factors laid out in its own disclosure rather than the primary endpoint alone, including a secondary measure that the company says showed clearer separation from placebo. There is also company-specific history behind this cautious, evidence-driven framing: Acadia's approved drug Nuplazid, or pimavanserin, already treats Parkinson's disease psychosis, giving the company direct experience developing and defending psychosis therapies through the regulatory process.
The Unmet Need Acadia Is Targeting
The company's release frames the market opportunity in stark terms, noting that roughly 30% of the more than 7 million Americans living with Alzheimer's disease experience psychosis symptoms such as hallucinations or delusions, a population for which no therapy is currently approved specifically for this indication.
What It Means for Investors
The topline numbers here are genuinely mixed: a primary endpoint miss is a primary endpoint miss, and a p-value of 0.0603 is not statistically significant by conventional standards, even as the company argues the broader data package justifies moving forward. Investors weighing the program's risk should treat Acadia's own framing as the company's interpretation, not a regulatory determination, since the FDA will ultimately decide what evidence is sufficient to support approval.
The Data Presentation Still to Come
Acadia says it will present detailed RADIANT results at the Clinical Trials on Alzheimer's Disease conference in Boston, scheduled for November, which should give investors and outside researchers a fuller picture of the secondary measures and subgroup data the company is citing to support its Phase 3 decision.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...